Atyr PHARMA (ATYR) News Today $2.99 -0.05 (-1.64%) (As of 11/20/2024 ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street TipRanks The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 Time Period aTyr Pharma to Present Posters on tRNA Synthetase Candidate ATYR0101 at Keystone Symposia on FibrosisNovember 15, 2024 | globenewswire.comAtyr PHARMA INC (NASDAQ:ATYR) Short Interest Up 55.1% in OctoberAtyr PHARMA INC (NASDAQ:ATYR - Get Free Report) saw a large increase in short interest in the month of October. As of October 31st, there was short interest totalling 1,660,000 shares, an increase of 55.1% from the October 15th total of 1,070,000 shares. Approximately 2.0% of the shares of the company are short sold. Based on an average daily trading volume, of 761,100 shares, the short-interest ratio is currently 2.2 days.November 14, 2024 | marketbeat.comaTyr Pharma Reports Q3 2024 Financial ResultsNovember 9, 2024 | markets.businessinsider.comaTyr Pharma Positioned for Success with Strong Financials and Pivotal Trial ResultsNovember 9, 2024 | markets.businessinsider.comAtyr PHARMA (NASDAQ:ATYR) Earns "Buy" Rating from HC WainwrightHC Wainwright reissued a "buy" rating and set a $35.00 target price on shares of Atyr PHARMA in a research report on Tuesday.October 29, 2024 | marketbeat.comShort Interest in Atyr PHARMA INC (NASDAQ:ATYR) Drops By 21.3%Atyr PHARMA INC (NASDAQ:ATYR - Get Free Report) was the target of a significant decline in short interest in October. As of October 15th, there was short interest totalling 1,070,000 shares, a decline of 21.3% from the September 30th total of 1,360,000 shares. Approximately 1.5% of the company's stock are sold short. Based on an average daily volume of 684,000 shares, the days-to-cover ratio is currently 1.6 days.October 28, 2024 | marketbeat.comAtyr PHARMA INC (NASDAQ:ATYR) Sees Significant Growth in Short InterestAtyr PHARMA INC (NASDAQ:ATYR - Get Free Report) saw a large increase in short interest in the month of September. As of September 30th, there was short interest totalling 1,360,000 shares, an increase of 98.3% from the September 15th total of 685,800 shares. Approximately 1.8% of the shares of the company are short sold. Based on an average daily trading volume, of 443,700 shares, the short-interest ratio is currently 3.1 days.October 11, 2024 | marketbeat.comAnalysts Offer Insights on Healthcare Companies: Sandoz Group Ltd (OtherSDZXF) and aTyr Pharma (ATYR)October 6, 2024 | markets.businessinsider.comaTyr Pharma, Inc. (ATYR) Stock Historical Prices & Data - Yahoo FinanceOctober 5, 2024 | ca.finance.yahoo.comWells Fargo Initiates Coverage of aTyr Pharma (ATYR) with Overweight RecommendationOctober 5, 2024 | msn.comAtyr PHARMA (NASDAQ:ATYR) Coverage Initiated at Wells Fargo & CompanyWells Fargo & Company began coverage on shares of Atyr PHARMA in a research note on Friday. They issued an "overweight" rating and a $17.00 price target on the stock.October 4, 2024 | marketbeat.comaTyr Pharma Announces Publication Demonstrating Efficacy of Efzofitimod in Pulmonary Sarcoidosis in the European Respiratory JournalOctober 2, 2024 | finance.yahoo.comShort Interest in Atyr PHARMA INC (NASDAQ:ATYR) Rises By 55.5%Atyr PHARMA INC (NASDAQ:ATYR - Get Free Report) was the recipient of a large increase in short interest in the month of September. As of September 15th, there was short interest totalling 685,800 shares, an increase of 55.5% from the August 31st total of 440,900 shares. Approximately 0.9% of the company's stock are sold short. Based on an average trading volume of 371,400 shares, the days-to-cover ratio is presently 1.8 days.September 27, 2024 | marketbeat.comAtyr PHARMA INC (NASDAQ:ATYR) Short Interest Up 27.1% in AugustAtyr PHARMA INC (NASDAQ:ATYR - Get Free Report) saw a large increase in short interest during the month of August. As of August 31st, there was short interest totalling 440,900 shares, an increase of 27.1% from the August 15th total of 346,800 shares. Approximately 0.6% of the shares of the company are sold short. Based on an average daily trading volume, of 387,800 shares, the days-to-cover ratio is presently 1.1 days.September 14, 2024 | marketbeat.comAtyr PHARMA INC (NASDAQ:ATYR) Sees Large Growth in Short InterestAtyr PHARMA INC (NASDAQ:ATYR - Get Free Report) saw a significant increase in short interest in August. As of August 15th, there was short interest totalling 346,800 shares, an increase of 28.2% from the July 31st total of 270,600 shares. Based on an average trading volume of 384,700 shares, the days-to-cover ratio is currently 0.9 days. Currently, 0.5% of the company's shares are short sold.August 30, 2024 | marketbeat.comaTyr Pharma to Participate in September Investor ConferencesAugust 21, 2024 | globenewswire.comaTyr Pharma, Inc. (ATYR)August 18, 2024 | uk.finance.yahoo.comAtyr PHARMA INC (NASDAQ:ATYR) Sees Large Decline in Short InterestAtyr PHARMA INC (NASDAQ:ATYR - Get Free Report) was the target of a large decline in short interest in July. As of July 31st, there was short interest totalling 270,600 shares, a decline of 19.6% from the July 15th total of 336,600 shares. Currently, 0.4% of the shares of the stock are short sold. Based on an average daily volume of 451,500 shares, the days-to-cover ratio is currently 0.6 days.August 17, 2024 | marketbeat.comQ3 2024 Earnings Estimate for Atyr PHARMA INC Issued By HC Wainwright (NASDAQ:ATYR)Atyr PHARMA INC (NASDAQ:ATYR - Free Report) - Research analysts at HC Wainwright increased their Q3 2024 earnings per share estimates for shares of Atyr PHARMA in a report released on Wednesday, August 14th. HC Wainwright analyst J. Pantginis now anticipates that the company will post earnings peAugust 16, 2024 | marketbeat.comIs aTyr Pharma (NASDAQ:ATYR) In A Good Position To Invest In Growth?August 15, 2024 | finance.yahoo.comAtyr PHARMA (NASDAQ:ATYR) Given "Outperform" Rating at Royal Bank of CanadaRoyal Bank of Canada reaffirmed an "outperform" rating and set a $16.00 price target on shares of Atyr PHARMA in a research note on Wednesday.August 14, 2024 | marketbeat.comAtyr PHARMA (NASDAQ:ATYR) Posts Quarterly Earnings Results, Beats Estimates By $0.01 EPSAtyr PHARMA (NASDAQ:ATYR - Get Free Report) announced its quarterly earnings data on Tuesday. The company reported ($0.23) earnings per share for the quarter, topping the consensus estimate of ($0.24) by $0.01.August 14, 2024 | marketbeat.comaTyr Pharma Announces Second Quarter 2024 Results and Provides Corporate UpdateAugust 13, 2024 | globenewswire.comAtyr PHARMA (NASDAQ:ATYR) Receives "Buy" Rating from HC WainwrightHC Wainwright reissued a "buy" rating and set a $35.00 target price on shares of Atyr PHARMA in a research note on Thursday.August 1, 2024 | marketbeat.comaTyr Pharma’s Strategic Advances in Clinical Research Bolster Buy RatingAugust 1, 2024 | markets.businessinsider.comAtyr PHARMA INC (NASDAQ:ATYR) Director Purchases $100,939.00 in StockJuly 25, 2024 | insidertrades.comAtyr PHARMA INC (NASDAQ:ATYR) Director Paul Schimmel Purchases 41,052 SharesJuly 25, 2024 | insidertrades.com Get Atyr PHARMA News Delivered to You Automatically Sign up to receive the latest news and ratings for ATYR and its competitors with MarketBeat's FREE daily newsletter. Email Address When it comes to NVDA… “acceleration cycles” are the key (Ad)Expert options trader Graham Lindman has been working on a new way to tap into Nvidia’s options… By simply isolating outsized “acceleration cycles” within Nvidia stock (most investors don’t even know it exists)... And thanks to many months and late nights working out the kinks of the systems… They have finally found a way to target these cycles on Nvidia over and over again. Use this link to see Nvidia Unchained right away! ATYR Media Mentions By Week ATYR Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ATYR News Sentiment▼0.970.45▲Average Medical News Sentiment ATYR News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ATYR Articles This Week▼11▲ATYR Articles Average Week Get Atyr PHARMA News Delivered to You Automatically Sign up to receive the latest news and ratings for ATYR and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Zymeworks News Septerna News Cogent Biosciences News Bicara Therapeutics News Bicycle Therapeutics News Collegium Pharmaceutical News Phibro Animal Health News Immatics News ArriVent BioPharma News Nuvation Bio News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ATYR) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Atyr PHARMA INC Please log in to your account or sign up in order to add this asset to your watchlist. Share Atyr PHARMA With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ATYR Stock Alerts